August 2026 brought promising Parkinson's disease research on everyday function, but no new novel FDA-approved Parkinson's therapy. The main developments were tavapadon trial results, preclinical NIH research, care-policy planning, and recruiting rehabilitation studies. "Daily living" means tasks such as dressing, bathing, walking, and managing routines. The new evidence may guide future care and research participation, but it does not establish a new treatment people can start now.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Check eligibility on ClinicalTrials.gov’s official study page — Use this page to check the study’s participation requirements.
- Read the original research from NIH — Use this page to review the original research.
Table of Contents
- Did the FDA approve a new Parkinson's treatment?
- What did the tavapadon trial find?
- How close is the NIH drug candidate to patients?
- Which studies are targeting everyday function?
- Key takeaways for practical decisions
Did the FDA approve a new Parkinson's treatment?
No new novel Parkinson's drug appeared on the FDA's 2026 approvals list through August 28. The list contained 36 novel-drug approvals, none for Parkinson's disease, according to the FDA's 2026 approval record. That finding has an important boundary.
The list tracks novel drugs, so it does not rule out every possible label change, formulation approval, or other regulatory action. For readers making treatment decisions, the practical message is that August's research headlines did not create a newly approved novel Parkinson's option. Investigational drugs and animal-study candidates should not be treated as available therapies.
What did the tavapadon trial find?
The August TEMPO-2 publication reported results in 304 adults with early Parkinson's disease. At week 26, once-daily tavapadon improved the combined daily-living and motor score by 9.1 points more than placebo, according to The Lancet Neurology record on PubMed. The combined outcome matters when interpreting the result.
It does not show how much of the difference came specifically from daily activities rather than motor symptoms. Tolerability also limits the finding. Thirty-eight percent of tavapadon participants discontinued, compared with 15% receiving placebo, most often because of adverse events. Tavapadon remains investigational and is not an FDA-approved treatment.
📨 Get Free Parkinson's Guides Alerts
Free · No spam · Unsubscribe anytime
How close is the NIH drug candidate to patients?
NIH highlighted SB-0107, which enhanced levodopa-related benefits and reduced dyskinesia-like effects in mouse and nonhuman-primate models. Dyskinesia refers to involuntary movement effects. NIH Research Matters described the August findings. This is preclinical research, meaning the candidate has not yet been established as a treatment for people.
The results may support further development, but they cannot show whether SB-0107 will be safe, effective, or available for patients. A separate NIH development concerned the National Plan to End Parkinson's. Its request for information covered research, care, services, and the physical, mental, social, and financial effects on people and caregivers. The response period closed August 22, making this a care-policy milestone rather than a new intervention.
Which studies are targeting everyday function?
Three recruiting studies address daily activities through exercise or occupational therapy. They represent opportunities to contribute to research, not proof that the tested programs work.
Before pursuing a study, confirm its current status and full eligibility requirements with the research team. Ask what exercises, visits, technology, and time commitments participation requires, and discuss safety with the clinician managing your Parkinson's care.
- An Ankara study is testing aquatic therapy plus land exercises in adults aged 40–80 with idiopathic Parkinson's disease. Outcomes include daily activities, walking, balance, posture, pain, and depression, as detailed in ClinicalTrials.gov record NCT07390825.
- A home-based study is evaluating high-speed bodyweight resistance training. It includes the activities-of-daily-living domain of the PDQ-39 questionnaire, but no results have been posted.
- A Chang Gung University trial combines an online program with task-related occupational-therapy training. It targets performance of daily activities and quality of life.
Key takeaways for practical decisions
The August evidence falls into four different stages: established availability, investigational human research, preclinical laboratory research, and recruiting rehabilitation studies. Keeping those stages separate prevents a promising result from being mistaken for an immediately usable treatment. Tavapadon offers the clearest human signal involving daily living, but its combined outcome and high discontinuation rate require caution.
SB-0107 remains preclinical, while the exercise and occupational-therapy studies cannot establish benefit until results are available. If daily activities are becoming harder now, do not wait for these candidates or change treatment based on a trial headline. Bring specific problem tasks to the treating clinician and use the exact ClinicalTrials.gov record when asking whether a study is appropriate.
You Might Also Like
- What Is New With Diet and Nutrition for Parkinson’s Disease in August 2026? Latest NIH, FDA, and trial records and Key Takeaways
- Daily Living for Parkinson’s Disease August 2026 Update: What Changed, Why It Matters, and What to Watch Next
- Traffic Noise May Increase Parkinson’s Disease Risk, New Study Suggests